Connecticut enforcement actions targeting compounded GLP-1 marketing in Med Spas expand as state and federal officials raise concerns about sourcing, advertising, and prescribing practices.
Connecticut Officials Urge Caution on Non-FDA-Approved GLP-1 Drugs
On April 9, 2026, Connecticut Attorney General William Tong and U.S. Senator Richard Blumenthal warned consumers about the risks associated with compounded and unapproved GLP-1 drugs. The statements follow a May 21, 2025, warning issued to clinics and Med Spas regarding the marketing of compounded GLP-1 drugs. In December 2025, cease-and-desist letters were sent to businesses advertising these products, which the Office of the Attorney General stated may violate the Connecticut Unfair Trade Practices Act. The enforcement activity centers on GLP-1 weight-loss services marketed and administered in Med Spa and clinic settings.
Timeline of Connecticut Officials’ Actions on Compounded GLP-1 Enforcement
Connecticut officials have taken enforcement actions addressing the marketing and sale of compounded GLP-1 drugs, including those offered in Med Spa and clinic settings. A May 21, 2025, warning from the Office of the Attorney General notified healthcare providers, including Med Spas, that advertising and selling compounded GLP-1 drugs could violate the Connecticut Unfair Trade Practices Act, particularly when promoted as “generic” or FDA-approved alternatives.
In December 2025, Attorney General William Tong announced in a press release that cease-and-desist letters were sent to several businesses, including weight-loss clinics and Med Spa-related operations, targeting misleading advertising for compounded semaglutide and tirzepatide. The enforcement actions cited claims that these products were FDA-approved or equivalent to branded drugs, as well as concerns involving unlicensed ownership of businesses providing medical services.
Earlier actions in 2025 also included a settlement requiring a company to stop selling what officials described as “bootleg GLP-1 drugs” and an investigation into online platforms marketing “research-grade” GLP-1 substances to U.S. consumers. The December 2025 press release also noted that state officials joined a multistate request urging increased federal enforcement against suppliers of counterfeit and unapproved GLP-1 products.
On April 9, 2026, Attorney General Tong and U.S. Senator Richard Blumenthal addressed these issues during a press conference in Hartford, as reported by CT Insider. The officials warned consumers about compounded and unapproved GLP-1 drugs and emphasized obtaining medications through licensed providers. The statements referenced prior enforcement actions involving clinics and Med Spas and ongoing oversight of GLP-1-related services.
DISCOVER YOUR MED SPA’S GROWTH POTENTIAL
How much time and revenue could you unlock by outsourcing your GFEs?
Use our GFE Calculator to find out in under 5 minutes. It’s quick, easy, and tailored to your Med Spa.
Source Attribution
According to reporting by CT Insider, Connecticut Attorney General William Tong and U.S. Senator Richard Blumenthal addressed compounded GLP-1 drugs during an April 9, 2026, press conference in Hartford. Additional details are based on a May 21, 2025, warning letter, a December 3, 2025, enforcement announcement issued by the Connecticut Office of the Attorney General, and April 1, 2026, guidance published by the U.S. Food and Drug Administration.
Compliance Considerations for GLP-1 Services in Med Spa Settings
Connecticut enforcement actions identify compliance risks tied to the marketing, sourcing, and provision of compounded GLP-1 drugs in Med Spa and clinic settings. The Office of the Attorney General cited FDA-identified concerns, including dosing errors, use of salt forms of active ingredients, and adverse event reports associated with compounded products.
On April 1, 2026, the U.S. Food and Drug Administration clarified that compounded GLP-1 drugs are subject to limitations under federal law, including restrictions when products are no longer in shortage and when compounded versions are essentially copies of commercially available drugs.
The enforcement actions identified several regulatory focus areas, including advertising practices, drug sourcing, prescribing conditions, and business ownership. The Office of the Attorney General cited marketing that presented compounded products as FDA-approved, “generic,” or clinically tested, as well as sourcing practices involving bulk ingredients such as salt forms. The actions also addressed prescribing practices that did not align with federal compounding conditions and business structures in which medical services were offered without licensed healthcare providers.
Federal oversight has also addressed GLP-1 prescribing and marketing practices in telehealth-based models and prescriber oversight. State-level enforcement has addressed clinical supervision and infection control in Med Spa settings, including a February 14, 2025, disciplinary case brought by the Connecticut Department of Public Health.
The actions taken by Connecticut officials apply to GLP-1 services offered in Med Spa settings and reflect how state requirements and federal guidance are applied to these practices.
Practical Implications for Med Spa Operators
Based on the enforcement actions cited by the Connecticut Attorney General, key compliance considerations include:
- Verify that compounded GLP-1 medications are prepared and dispensed in accordance with applicable federal requirements
- Confirm that services involving prescription medications are performed under appropriate licensed provider oversight
- Document provider evaluation, prescription, and clinical decision-making for all GLP-1 treatments
- Ensure marketing and patient-facing materials do not present compounded medications as FDA-approved or as equivalents to branded drugs
- Maintain records showing how GLP-1 medications are sourced, handled, and administered within the practice
- Review business ownership and operational structure to ensure compliance with state requirements for medical services
What to Watch
Connecticut officials have indicated ongoing enforcement activity, including investigations related to product sourcing and online distribution channels. At the federal level, the U.S. Food and Drug Administration continues oversight of compounding practices and supplier activity, particularly where products are marketed outside approved conditions.
Additional guidance or enforcement actions may further clarify how these requirements are applied.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Connecticut State Capitol, Hartford” by jglazer75, via Wikimedia Commons, licensed under CC BY 2.0.
